BMS 986184

Drug Profile

BMS 986184

Alternative Names: BMS-986184

Latest Information Update: 30 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Monoclonal antibodies
  • Mechanism of Action Chemokine CXCL10 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ulcerative colitis

Most Recent Events

  • 27 Sep 2017 Bristol-Myers Squibb terminates a phase I trial in Ulcerative colitis in Australia, Georgia, Moldova due to adverse change in the risk/benefit (IV) (SC)
  • 01 Sep 2016 Phase-I clinical trials in Ulcerative colitis in Australia (IV) (NCT02864264)
  • 01 Sep 2016 Phase-I clinical trials in Ulcerative colitis in Australia (SC) (NCT02864264)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top